Actively Recruiting

Atopic Dermatitis

Real world utilization of upadacitinib in adoult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)

Study Contact: Madeleine Smee

Cat Allergy

A Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home

Study Contact: Susi Snitzler


Chronic Spontaneous Urticaria

A Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria(INCEPTION)

Study Contact: Wael Mohammed

A randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate to severe chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment, and who are naive to omalizumab (RILECSU)

Study Contact: Madeleline SMEE

Hereditary Angioedema

A Study to Evaluate the Safety and Efficacy of PHA-022121 Administration Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency(Type I or Type II) (Chapter-1)

Study Contact: Wael Mohammed

A Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or Type II (KVD824)

Study Contact: Leena Johnson Chacko

Nasal Polyps

Assessing Long-Term Outcomes of DUPIXENT Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyposis (AROMA)

Study Contact: Madeleine Smee

Peanut Allergy

A 52 week study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy

Study Contact: Susi Snitzler

Active Studies - Non Recruiting

Please take a look at active studies that have been closed to recruiting


Past Studies

Please take a look at past studies that have been done.